Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SupplySide West In Brief

This article was originally published in The Tan Sheet

Executive Summary

Cargill: Self-GRAS certification for Cargill's Regenasure glucosamine product gives the ingredient unique opportunities into the functional food arena, according to Technical Services Manager Brent Rogers. The glucosamine form, which launched in 2004, is available in supplement products, but "when Cargill did a self-GRAS of the product we opened up innovation with glucosamine for the first time in food products," Rogers said. Under DSHEA, self-GRAS allows a firm to gather safety data in order to certify an ingredient as generally recognized as safe. Additionally, "being the only domestically produced product has differentiated our product greatly, since most all of it comes from Asia, and ours is uniquely made from a patent-protected process which is a fermentation versus the traditional waste shells of shellfish; therefore this product is suitable for vegetarians and people with shellfish allergies," Rogers added. The firm included many varieties of beverages in addition to yogurt in its GRAS assessment and plans to explore applications in new food categories in the future. The firm debuted its first commercial Regenasure-containing beverage, Joint Juice, at the show; other show launches include a pomegranate dairy smoothie containing CoroWise plant sterols, a tropical strawberry yogurt smoothie with Oliggo-Fiber inulin and a strawberry chewy granola bar with Xtend sucromalt...

You may also be interested in...



SupplySide West In Brief

AREDS II rolling: Enrollment is complete and the second iteration of the National Eye Institute's Age-Related Eye Diseases Study is under way, according to Paul S. Bernstein, a researcher and professor of ophthalmology and visual sciences at the University of Utah School of Medicine's John A. Moran Eye Center. At the SupplySide West trade show in Las Vegas Oct. 22, Bernstein said through 2013, AREDS II will follow 4,000 patients between the ages of 50 and 85 with high risk for age-related macular degeneration at 100 U.S. sites. He explained that the antioxidant formulation for the first AREDS was "based on the best science of the 1980s" and omitted lutein and zeaxanthin, but the AREDS II formulation includes those carotenoids at levels about five times greater than a typical American diet. The revised formulation also lowers the original zinc and beta-carotene levels due to concerns about urinary tract problems and lung cancer, respectively. The AREDS results, released in 2001, showed high-dose antioxidant vitamins and minerals reduce the risk of advanced AMD progression by 25 percent (1"The Tan Sheet" Jan. 21, 2008, p. 14)

SupplySide West In Brief

AREDS II rolling: Enrollment is complete and the second iteration of the National Eye Institute's Age-Related Eye Diseases Study is under way, according to Paul S. Bernstein, a researcher and professor of ophthalmology and visual sciences at the University of Utah School of Medicine's John A. Moran Eye Center. At the SupplySide West trade show in Las Vegas Oct. 22, Bernstein said through 2013, AREDS II will follow 4,000 patients between the ages of 50 and 85 with high risk for age-related macular degeneration at 100 U.S. sites. He explained that the antioxidant formulation for the first AREDS was "based on the best science of the 1980s" and omitted lutein and zeaxanthin, but the AREDS II formulation includes those carotenoids at levels about five times greater than a typical American diet. The revised formulation also lowers the original zinc and beta-carotene levels due to concerns about urinary tract problems and lung cancer, respectively. The AREDS results, released in 2001, showed high-dose antioxidant vitamins and minerals reduce the risk of advanced AMD progression by 25 percent (1"The Tan Sheet" Jan. 21, 2008, p. 14)

SupplySide West In Brief

AREDS II rolling: Enrollment is complete and the second iteration of the National Eye Institute's Age-Related Eye Diseases Study is under way, according to Paul S. Bernstein, a researcher and professor of ophthalmology and visual sciences at the University of Utah School of Medicine's John A. Moran Eye Center. At the SupplySide West trade show in Las Vegas Oct. 22, Bernstein said through 2013, AREDS II will follow 4,000 patients between the ages of 50 and 85 with high risk for age-related macular degeneration at 100 U.S. sites. He explained that the antioxidant formulation for the first AREDS was "based on the best science of the 1980s" and omitted lutein and zeaxanthin, but the AREDS II formulation includes those carotenoids at levels about five times greater than a typical American diet. The revised formulation also lowers the original zinc and beta-carotene levels due to concerns about urinary tract problems and lung cancer, respectively. The AREDS results, released in 2001, showed high-dose antioxidant vitamins and minerals reduce the risk of advanced AMD progression by 25 percent (1"The Tan Sheet" Jan. 21, 2008, p. 14)

Topics

UsernamePublicRestriction

Register

PS101120

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel